Republicans Consider Defeated Sen. Roger Marshall as Backup FDA Nominee Amid Confirmation Struggles
Key Takeaways
- •Congressional Republicans are considering recently defeated Sen. Roger Marshall as a backup candidate to lead the FDA because current nominee Heidi Overton has struggled to advance through Senate confirmation.
- •The Senate Health Committee is set to vote Wednesday on Overton's nomination, which has drawn criticism over her lack of experience and a letter from hundreds of medical providers urging rejection over her views on reproductive rights.
- •Marshall, a physician and staunch Trump ally, lost his Kansas Senate seat to Democrat Adam Hamilton by six points, with his term ending in January when Democrats assume the Senate majority.
- •Marshall's defeat was worsened by revelations that, while practicing as an obstetrician, he sued more than 700 patients over unpaid bills, charging up to 18 percent in late fees, with some lawsuits sending patients to jail.
- •The FDA has been without a permanent commissioner since Marty Makary was pushed out in May, and acting Commissioner Kyle Diamantas is reportedly eyeing a departure from the agency regardless of Overton's confirmation outcome.

New reporting on Tuesday revealed that congressional Republicans are weighing recently defeated Sen. Roger Marshall (R-KS) as a candidate to lead the Food and Drug Administration, as the party races to confirm last-minute nominees before Democrats take the Senate majority in January. Marshall's name has surfaced because current FDA nominee Heidi Overton has struggled to advance through the Senate confirmation process amid opposition from moderate Republicans.
"Marshall is viewed as an alternative if Heidi can't make it through," a Trump administration official told Semafor. "Senators have an easier time getting confirmed, traditionally. At this point, it's hard to get anyone approved."
The Senate Health Committee is scheduled to vote on Overton's nomination on Wednesday. The outcome will determine whether her nomination can advance to the full Senate for final confirmation. Critics, however, say she lacks the experience necessary to oversee a large organization like the FDA, and hundreds of medical providers have signed a letter urging senators to reject her confirmation over concerns about her extreme views on reproductive rights. Her principal qualification for the nomination appears to be her involvement with the MAGA think tank America First Policy Institute.
The GOP's potential replacement, though, is also firmly in the MAGA camp. Marshall, a physician who served two terms in the House before winning his Senate seat in 2020, lost his reelection bid in Kansas to Democrat Adam Hamilton — handing the state its first Democratic senator in nearly 100 years. His term ends in January, when the Democratically controlled Senate is seated — the same deadline squeezing the party's entire confirmation push. Long considered a staunch ally of President Donald Trump and his policy agenda, Marshall ran, and lost, under the president's endorsement.
"There is a growing view in the Senate that a senator would be the only person while we've got a majority so Roger Marshall's name is quickly percolating as a person who would be confirmable," a senior Republican aide said.
Yet Marshall's six-point defeat — a blowout by Kansas's deeply red standards — is not his only potential liability. Revelations about his medical practice were a key factor in his loss: while practicing as an obstetrician, he sued more than 700 patients over unpaid, sometimes low-dollar medical bills, charging as much as 18 percent on late payments, with some lawsuits landing patients in jail. Despite the election-losing scandal, the GOP appears to view him as the party's best hope of squeaking out a final-hour confirmation.
The FDA has been without a permanent leader for months. According to Semafor, the agency has operated under acting leadership since former Commissioner Marty Makary was pushed out in May after clashing with the White House over whether to authorize flavored vapes. Makary also faced pressure from anti-abortion Republicans who are pushing for restrictions on the abortion pill mifepristone. Because the commissioner is a Senate-confirmed post, the agency cannot install permanent leadership until a nominee clears the same process now testing Overton — a bottleneck that explains why senators are scanning their own ranks for a confirmable name.
Kyle Diamantas, a lawyer who worked as the agency's top food official, was tapped as acting FDA commissioner and earned a reputation as a competent leader who helped stabilize the agency. But the Trump administration official said Diamantas — who did not want the top job on a permanent basis — is eyeing a departure from the FDA regardless of what happens with Overton's nomination. If he follows through, the agency would be left searching for new acting leadership even as the commissioner question remains unresolved.